Oramed Pharmaceuticals Inc SEC Filings

Oramed Pharmaceuticals (ORMP) director and Chief Scientific Officer Miriam Kidron reported the vesting of performance stock units (PSUs) into common shares. On January 22, 2026, 19,000 PSUs vested after Oramed’s common stock reached a specified price level.

Each PSU converted into one share of common stock, so Kidron received 19,000 shares of Oramed common stock for no cash consideration. Following this equity-based award, she directly beneficially owns 1,448,664 shares of Oramed common stock, reflecting her ongoing equity stake in the company.

Oramed Pharmaceuticals Inc. Chief Financial Officer Avraham Gabay reported the vesting of 19,000 performance stock units into common shares. The PSUs were granted on December 31, 2025 and vested on January 22, 2026 after Oramed’s common stock reached a specified price per share.

Each PSU converted into one share of common stock, and the shares were received for no cash consideration. Following this transaction, Gabay directly beneficially owns 649,256 shares of Oramed common stock.

Oramed Pharmaceuticals Inc. insider filing: President and CEO Nadav Kidron reported the vesting of performance stock units tied to Oramed’s share price. On January 22, 2026, 109,000 PSUs converted into 109,000 shares of common stock for no cash consideration.

Each PSU gave the right to receive one share when specific performance criteria were met. Following this vesting, Kidron directly owns 3,355,238 shares of Oramed common stock.

Oramed Pharmaceuticals director and Chief Scientific Officer Miriam Kidron reported a charitable donation of company stock. On 01/14/2026, she gifted 86,166 shares of Oramed Pharmaceuticals Inc. common stock in a transaction coded "G," which is designated for gifts. The filing states this was a charitable donation, not a market trade, so no price was reported and no value was received for the shares.

After the donation, Kidron beneficially owned 1,343,498 shares of Oramed common stock in direct ownership form. The footnote adds that she is not affiliated with, and has no control over, the recipient organization.

Oramed Pharmaceuticals signed a major deal with Lifeward Ltd. to sell all of its Oratech Pharma subsidiary. In return, Oramed will receive Lifeward ordinary shares, very low-priced pre-funded warrants, and additional warrants that together could give it up to 49.99% of Lifeward’s fully diluted equity, subject to ownership limits and shareholder approval. Oramed will also receive 4% of net revenue from Lifeward’s ReWalk Personal Exoskeleton products until a time or value cap is reached or Lifeward’s market value hits $200 million.

Separately, Oramed agreed to buy $9,000,000 of senior secured convertible notes from Lifeward now, with an option for another $9,000,000 later if performance or share price targets are met. These notes and related warrants are convertible into Lifeward shares at an initial price of $0.45 per share, with anti-dilution adjustments and caps to keep Oramed’s ownership initially below 45.0%. Oramed also committed to a 120‑day lock-up on Lifeward securities it receives and will manage Oratech’s oral insulin clinical study under a reimbursed services agreement.

Oramed Pharmaceuticals Inc. reported that it has received an $18 million payment from Scilex Holdings Inc., which represents full satisfaction of Scilex’s obligations under their Option Agreement. This adds a significant amount of cash to the company.

The company’s board also approved a cash dividend of $0.25 per share to reward stockholders, for a total distribution of approximately $10.5 million based on the current shares outstanding. The dividend will be paid on January 26, 2026 to stockholders of record as of January 16, 2026, and will be funded from the company’s surplus capital.

Oramed Pharmaceuticals Inc. filed a current report announcing that it has released unaudited financial results for the nine months ended September 30, 2025. The company disclosed these results in a press release dated November 17, 2025, which is included as Exhibit 99.1 to the report. The financial information is provided under Item 2.02, meaning it is being furnished rather than filed and therefore is not subject to certain liability provisions under the Exchange Act or automatically incorporated into other securities filings. Oramed’s common stock continues to trade on The Nasdaq Capital Market and the Tel Aviv Stock Exchange under the symbol ORMP.

Oramed Pharmaceuticals Inc. adopted a shareholder rights plan by declaring a dividend of one common stock purchase right for each outstanding share of common stock. The dividend will be paid on November 27, 2025 to holders of record on that date. Each right initially allows the holder to buy one share of common stock from the company at $10.00 per share, subject to adjustment. The rights become separable and trade independently only if a person or group acquires, or launches an offer to acquire, generally 15% or more of Oramed’s common stock. If that happens, other right holders can acquire common stock (or, in some cases, stock of an acquiring company) with a market value equal to two times the exercise price, while the acquiring person’s rights become void. The rights expire three years after the agreement date unless earlier redeemed by the board at $0.012 per right or exchanged for common stock.

Oramed Pharmaceuticals (ORMP) reported a swing to profitability driven by investment revaluations. For the nine months ended September 30, 2025, net income attributable to stockholders was $54,041 thousand, including third‑quarter net income of $48,395 thousand. Financial income, net, reached $74,278 thousand, reflecting fair value gains primarily on Alpha Tau and Scilex exposures.

Total assets were $220,493 thousand with stockholders’ equity of $203,282 thousand. Cash and cash equivalents were $52,179 thousand. The company recognized $2,000 thousand of revenue tied to the HTIT License Agreement, while cost of revenue of $1,987 thousand related to IIA obligations.

Oramed expanded its investment portfolio: its Alpha Tau stake measured at fair value was $64,803 thousand, and it holds a 50% interest in RoyaltyVest. With Scilex, Oramed received $13,000 thousand from the repurchase of 3,130,000 Subsequent Penny Warrants and retains an option for $14,000 thousand on 3,370,000 additional warrants on or before December 31, 2025. The company also continued a buyback program, repurchasing $732 thousand of shares year‑to‑date.